New drug GT801 tested for tough autoimmune cases

NCT ID NCT07333118

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT801 injection (a biological drug)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat autoimmune diseases like lupus.
What could go wrong: This is a very early, small trial (22 people) focused mainly on safety. The treatment may not work or could have side effects. Much more research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease idiopathic inflammatory myopathy systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE TO SEVERE REFRACTORY AUTOIMMUNE DISEASE

Contacts and locations

Locations

Shanghai Changzheng Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.